相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。Evaluating the impact of study-level factors on warfarin control in US-based primary studies: A meta-analysis
Deborah A. Cios et al.
AMERICAN JOURNAL OF HEALTH-SYSTEM PHARMACY (2009)
Should We Be Applying Warfarin Pharmacogenetics to Clinical Practice? No, Not Now
Michael H. Rosove et al.
ANNALS OF INTERNAL MEDICINE (2009)
Relative contribution of CYP2C9 and VKORC1 genotypes and early INR response to the prediction of warfarin sensitivity during initiation of therapy
Chun Li et al.
BLOOD (2009)
The largest prospective warfarin-treated cohort supports genetic forecasting
Mia Wadelius et al.
BLOOD (2009)
Pharmacogenetic relevance of CYP4F2 V433M polymorphism on acenocoumarol therapy
Virginia Perez-Andreu et al.
BLOOD (2009)
Clopidogrel and the Concept of High-Risk Pharmacokinetics
Dan M. Roden et al.
CIRCULATION (2009)
Genotypes Associated With Reduced Activity of VKORC1 and CYP2C9 and Their Modification of Acenocoumarol Anticoagulation During the Initial Treatment Period
M. Teichert et al.
CLINICAL PHARMACOLOGY & THERAPEUTICS (2009)
Influence of CYP2C9 genotype on warfarin dose requirements-a systematic review and meta-analysis
Jonatan D. Lindh et al.
EUROPEAN JOURNAL OF CLINICAL PHARMACOLOGY (2009)
A genome-wide association study of acenocoumarol maintenance dosage
Martina Teichert et al.
HUMAN MOLECULAR GENETICS (2009)
Predicting warfarin maintenance dose in patients with venous thromboembolism based on the response to a standardized warfarin initiation nomogram
A. Lazo-Langner et al.
JOURNAL OF THROMBOSIS AND HAEMOSTASIS (2009)
CYP4F2 Is a Vitamin K1 Oxidase: An Explanation for Altered Warfarin Dose in Carriers of the V433M Variant
Matthew G. McDonald et al.
MOLECULAR PHARMACOLOGY (2009)
Estimation of the Warfarin Dose with Clinical and Pharmacogenetic Data
NEW ENGLAND JOURNAL OF MEDICINE (2009)
CYP4F2 genetic variant (rs2108622) significantly contributes to warfarin dosing variability in the Italian population
P. Borgiani et al.
PHARMACOGENOMICS (2009)
CYP2C9*8 is prevalent among African-Americans: implications for pharmacogenetic dosing
Stuart A. Scott et al.
PHARMACOGENOMICS (2009)
A Genome-Wide Association Study Confirms VKORC1, CYP2C9, and CYP4F2 as Principal Genetic Determinants of Warfarin Dose
Fumihiko Takeuchi et al.
PLOS GENETICS (2009)
Warfarin pharmacogenetics:: CYP2C9 and VKORC1 genotypes predict different sensitivity and resistance frequencies in the Ashkenazi and Sephardi Jewish populations
Stuart A. Scott et al.
AMERICAN JOURNAL OF HUMAN GENETICS (2008)
Delivery of optimized anticoagulant therapy: Consensus statement from the anticoagulation forum
David A. Garcia et al.
ANNALS OF PHARMACOTHERAPY (2008)
CYP4F2 genetic variant alters required warfarin dose
Michael D. Caldwell et al.
BLOOD (2008)
VKORC1 Asp36Tyr warfarin resistance marker is common in Ethiopian individuals
Eleni Aklillu et al.
BLOOD (2008)
Regulatory polymorphism in vitamin K epoxide reductase complex subunit 1 (VKORC1) affects gene expression and warfarin dose requirement
Danxin Wang et al.
BLOOD (2008)
A genome-wide scan for common genetic variants with a large influence on warfarin maintenance dose
Gregory M. Cooper et al.
BLOOD (2008)
Pharmacology and management of the vitamin K antagonists
Jack Ansell et al.
CHEST (2008)
Pharmacogenetics of oral anticoagulants - A basis for dose individualization
Simone Stehle et al.
CLINICAL PHARMACOKINETICS (2008)
Use of pharmacogenetic and clinical factors to predict the therapeutic dose of warfarin
B. F. Gage et al.
CLINICAL PHARMACOLOGY & THERAPEUTICS (2008)
Evidence for a pharmacogenetic adapted dose of oral anticoagulant in routine medical practice
Laurent Becquemont
EUROPEAN JOURNAL OF CLINICAL PHARMACOLOGY (2008)
Pharmacogenetic testing of CYP2C9 and VKORC1 alleles for warfarin
David A. Flockhart et al.
GENETICS IN MEDICINE (2008)
Laboratory and clinical outcomes of pharmacogenetic vs. clinical protocols for warfarin initiation in orthopedic patients
P. A. Lenzini et al.
JOURNAL OF THROMBOSIS AND HAEMOSTASIS (2008)
Genetic determinants of response to warfarin during initial anticoagulation
Ute I. Schwarz et al.
NEW ENGLAND JOURNAL OF MEDICINE (2008)
VKORC1 polymorphisms, haplotypes and haplotype groups on warfarin dose among African-Americans and European-Americans
Nita A. Limdi et al.
PHARMACOGENOMICS (2008)
Combination of phenotype assessments and CYP2C9-VKORC1 polymorphisms in the determination of warfarin dose requirements in heavily medicated patients
V. Michaud et al.
CLINICAL PHARMACOLOGY & THERAPEUTICS (2008)
CYP2C9 genotype-guided warfarin prescribing enhances the efficacy and safety of anticoagulation:: A prospective randomized controlled study
Y. Caraco et al.
CLINICAL PHARMACOLOGY & THERAPEUTICS (2008)
Influence of CYP2C9 and VKORC1 1173C/T genotype on the risk of hemorrhagic complications in African-American and European-American patients on warfarin
Na Limdi et al.
CLINICAL PHARMACOLOGY & THERAPEUTICS (2008)
Randomized trial of genotype-guided versus standard warfarin dosing in patients initiating oral anticoagulation
Jeffrey L. Anderson et al.
CIRCULATION (2007)
Genetic-based dosing in orthopedic patients beginning warfarin therapy
Eric A. Millican et al.
BLOOD (2007)
Bleeding complications with warfarin use - A prevalent adverse effect resulting in regulatory action
Diane K. Wysowski et al.
ARCHIVES OF INTERNAL MEDICINE (2007)
Use of genetic and nongenetic factors in warfarin dosing algorithms
Alan H. B. Wu
PHARMACOGENOMICS (2007)
A coding VKORC1 Asp36Tyr polymorphism predisposes to warfarin resistance
Ronen Loebstein et al.
BLOOD (2007)
Pharmacogenetics of warfarin: current status and future challenges
M. Wadelius et al.
PHARMACOGENOMICS JOURNAL (2007)
Different contributions of polymorphisms in VKORC1 and CYP2C9 to intra- and inter-population differences in maintenance dose of warfarin in Japanese, Caucasians and African-Americans
Harumi Takahashi et al.
PHARMACOGENETICS AND GENOMICS (2006)
In-vitro and in-vivo effects of the CYP2C9*11 polymorphism on warfarin metabolism and dose
GY Tai et al.
PHARMACOGENETICS AND GENOMICS (2005)
Effect of VKORC1 haplotypes on transcriptional regulation and warfarin dose
MJ Rieder et al.
NEW ENGLAND JOURNAL OF MEDICINE (2005)
CYP2C9 haplotype structure in European American warfarin patients and association with clinical outcomes
DL Veenstra et al.
CLINICAL PHARMACOLOGY & THERAPEUTICS (2005)
Equal proportion of adult male and female homozygous for the 677C→T mutation in the methylenetetrahydrofolate reductase polymorphism
CAM Anderson et al.
AMERICAN JOURNAL OF MEDICAL GENETICS PART A (2005)
A polymorphism in the VKORC1 gene is associated with an interindividual variability in the dose-anticoagulant effect of warfarin
G D'Andrea et al.
BLOOD (2005)
Clinical consequences of cytochrome P4502C9 polymorphisms
J Kirchheiner et al.
CLINICAL PHARMACOLOGY & THERAPEUTICS (2005)
Identification of the gene for vitamin K epoxide reductase
T Li et al.
NATURE (2004)
Mutations in VKORC1 cause warfarin resistance and multiple coagulation factor deficiency type 2
S Rost et al.
NATURE (2004)
Upstream and coding region CYP2C9 polymorphisms: correlation with warfarin dose and metabolism
BP King et al.
PHARMACOGENETICS (2004)
Clinical impact of bleeding in patients taking oral anticoagulant therapy for venous thromboembolism - A meta-analysis
LA Linkins et al.
ANNALS OF INTERNAL MEDICINE (2003)
Effect of intensity of oral anticoagulation on stroke severity and mortality in atrial fibrillation
EM Hylek et al.
NEW ENGLAND JOURNAL OF MEDICINE (2003)
Pharmacogenetics of CYP2C9 and interindividual variability in anticoagulant response to warfarin
H Takahashi et al.
PHARMACOGENOMICS JOURNAL (2003)
Influence of CYP2C9 and CYP2C19 genetic polymorphisms on warfarin maintenance dose and metabolic clearance
MG Scordo et al.
CLINICAL PHARMACOLOGY & THERAPEUTICS (2002)
Interindividual variability in sensitivity to warfarin - Nature or nurture?
R Loebstein et al.
CLINICAL PHARMACOLOGY & THERAPEUTICS (2001)
分享论文
